MedTrace Logo

Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

NCT04254640 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2020-12-17

No results posted yet for this study

Summary

In this study, the investigators conducted a phase II trial that evaluated the efficacy and safety of cladribine in combination with modified CAG regimen (low-dose cytarabine and aclarubicin) in elderly patients with AML.

Conditions

Interventions

DRUG

Cladribine Injection

Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.

DRUG

Aclarubicin

aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.

DRUG

G-CSF

G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.

DRUG

cytarabine

cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • wang hua, MD. · sun yat-sun university cancer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-06-01
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04254640 on ClinicalTrials.gov